-
Boya Ji completes the initiation of Phase I clinical trial for the treatment of β-thalassemia gene editing therapy and the first patient enrolled in the group, Dr. Mai Meng broke the news
Time of Update: 2021-10-02
Recent popular reports from Yimaike ★NoticeShanghai Minhang Biopharmaceutical Industry Development Conference and 2021 Life and Health Industry Summit Forum is about to open in Shanghai ★September·Sh
-
【Cell Journal】Large-scale genome-wide association study-early screening of neonatal acute lymphoblastic leukemia
Time of Update: 2021-10-02
Author: Daisy Guide: Recently, a study published in "American Journal of Human Genetics" showed that in a large-scale genome-wide association study, it was found that genetic Children who are prone to produce a large number of lymphocytes, especially related to monocytes, neutrophils and platelets, increase the risk of children suffering from acute lymphoblastic leukemia (ALL) by 20% or more .
-
2021 IMW Big Coffee Commentary | Professor Chen Wenming's interpretation of ide-cel treatment of RRMM
Time of Update: 2021-10-02
Research topic A BCMA-targeted CAR-T cell therapy idecabtagene vicleucel (ide-cel, bb2121) for the treatment of patients with relapsed and refractory multiple myeloma (RRMM): the latest results from the KarMMa study The research method has previously received ≥3 lines of treatment (Including immunomodulators, PI, and anti-CD38 monoclonal antibodies) and patients who are refractory to the last treatment plan are eligible for enrollment .
-
Express delivery of approximately US$1.9 billion won the first ROCK2 inhibitor approved, Sanofi expands its transplant drug pipeline
Time of Update: 2021-10-02
The acquisition will add Kadmon's small molecule therapy Rezurock (belumosudil) to its transplant portfolio .
"Reference: [1] Sanofi to acquire Kadmon to further strengthen growth of transplant business.
Retrieved 2021-09-08, from https:// /en/Sanofi-to-acquire-Kadmon-to-further-strengthen-growth-of-transplant-business.
-
CCSC: Real knowledge from practice, CAR-T's actual battle in the treatment of hematological tumors
Time of Update: 2021-10-01
In this session, Professor Wang Ying from the Hospital of Hematology of the Chinese Academy of Medical Sciences shared an introduction entitled "The translation of HI CAR T-cell therapy" .
-
Anti-BCMA CAR-T therapy is effective for relapsed and refractory multiple myeloma
Time of Update: 2021-10-01
In the latest development of the therapy, a Phase 1b/2, open-label clinical trial of CAR-T ciltacabtagene autoleucel that targets BCMA, funded by a pharmaceutical manufacturer, evaluated patients with relapsed or refractory MM who have undergone extensive treatment The overall response rate (ORR) and toxicity after CAR-T treatment .
-
2021 SOHO Big Coffee Commentary | Professor Liu Jiajun's interpretation of the real-world study of the treatment of AML patients with Venecla regimen
Time of Update: 2021-10-01
The results of the study showed that compared with the control group, the combination of Venecla and azacitidine increased the median survival of AML patients by 50% (14.
-
CCSC: Kylin Club International Connection—Stars are dazzling, big names gather to explore the international clinical application of CAR-T—Special session of Jiangsu Provincial People's Hospital
Time of Update: 2021-10-01
On June 22, 2021, the National Medical Products Administration (NMPA) officially approved Fosun Kate’s CD19 autologous CAR-T cell therapy drug Yikaida® (Akilunza injection) to fill the domestic long-term CAR-T drug Blank, as the first CAR-T cell therapy approved for marketing in China, it is used to treat adult patients with relapsed or refractory large B-cell lymphoma (R/R LBCL) after receiving second-line or above systemic treatment.
-
World Lymphoma Day｜Professor Zhu Jun talks about the current status and future development of lymphoma diagnosis and treatment in my country
Time of Update: 2021-10-01
On this occasion, Yimaitong had the honor to invite Professor Zhu Jun from Peking University Cancer Hospital to share the status quo and future development of lymphoma diagnosis and treatment in China .
-
World Lymphoma Day｜Professor Huang Huiqiang takes you to learn about the new progress of Celinisol in the treatment of patients with peripheral T-cell lymphoma
Time of Update: 2021-10-01
Five-line treatment: from October 2020 to August 2021 Celiniso combined with gemcitabine and oxaliplatin (GEMOX), a total of 3 courses; Celiniso single-agent maintenance , A total of 5 courses; the best curative effect is CR, and the progression-free survival (PFS) is> 9 months .
-
2021 SOHO article understands the treatment progress of Fahrenheit's macroglobulinemia
Time of Update: 2021-10-01
A clinical study involving 106 patients with WM evaluated the efficacy of acatinib, with an ORR of 93% and a 24-month PFS rate of 80%-90% .
A number of clinical studies of covalent BTKi combined with immunochemotherapy and proteasome inhibitors for the treatment of WM patients are underway .
-
New triple therapy prolongs survival of patients with multiple myeloma
Time of Update: 2021-10-01
Comment This study confirmed the benefits of isatuximab added to the combination therapy of carfilzomib and dexamethasone in adult patients with relapsed or refractory myeloma, and their PFS and response depth were improved .
-
Express BeiGene BTK inhibitor wins third FDA indication
Time of Update: 2021-10-01
▎Editor of WuXi AppTec's content team On September 15, BeiGene announced that the US FDA has accelerated the approval of its Bruton's tyrosine kinase (BTK) inhibitor Baiyueze (Zebutinib) for therapeutic acceptance Adult patients with relapsed/refractory (R/R) marginal zone lymphoma (MZL) who have been treated with at least one anti-CD20 antibody .
-
Express targeting CD4, legendary biological CAR-T therapy starts clinical trials in the United States
Time of Update: 2021-10-01
▎ WuXi AppTec content team editor September 13, 2021, Legend Biotech announced that based on the IND application approved by the US FDA, it will start a phase 1 clinical trial of the cell therapy LB1901 under investigation for the treatment of adult relapse/ Refractory peripheral T-cell lymphoma (PTCL), or cutaneous T-cell lymphoma (CTCL) .
-
Experience Sharing of the Latest Approved PK Software from Other Stones (4): Experience in Turkey
Time of Update: 2021-10-01
The specific research design is shown in Figure 1: Figure 1 Turkey PK software use experience sharing Study design Turkey experience sharing-PK software clinical use outcome 5 Treatment profile before adjustment of preventive treatment plan All patients received rAHF 1-3 days a week -PFM preventive treatment, the therapeutic dose is 25.
-
2021 How SOHO treats Hodgkin's lymphoma that has failed immune checkpoint inhibitor treatment
Time of Update: 2021-10-01
The results of a number of phase II clinical studies have shown that although PD-1 monoclonal antibody treatment of relapsed/refractory (R/R) cHL patients has a low complete remission (CR) rate, it can achieve disease remission in about two-thirds of patients .
-
PNH Famous Doctors Lecture Hall No. 5 Professor Han Bing: PNH Treatment-Complications
Time of Update: 2021-10-01
This issue of "PNH Famous Doctors Lecture" Yimaitong invited Professor Han Bing from Peking Union Medical College Hospital to share on the mechanism and treatment management of PNH renal complications and pulmonary hypertension complications!
-
The development of factor A replacement therapy in hemophilia and the deletion of rFⅧ in B area
Time of Update: 2021-10-01
The origin of recombinant human coagulation factor VIII (BDD-rFⅧ) deleted in B region is different from other genetic recombinant proteins.
A prospective surveillance study of inhibitor development in haemophilia A patients following a population switch to a third-generation B-domain-deleted recombinant factor VIII.
-
9.22 International Chronic Granules Professor Jiang Qian: The third generation of TKI drugs in China is expected to break the predicament of drug resistance and benefit more patients
Time of Update: 2021-10-01
On the occasion of the 20th anniversary of the "International CML Day" and targeted therapy, Professor Jiang Qian, deputy director of the Department of Hematology, Peking University People's Hospital, conducted popular science on the knowledge of chronic particles and the current status of diagnosis and treatment .
-
The latest research of Professor Zhu Xiaofan’s team by Lancet oncol is a subtraction for the treatment of childhood leukemia. The two chemotherapeutics with the greatest adverse reactions can be eliminated.
Time of Update: 2021-10-01
Recently, Professor Zhu Xiaofan’s research group from the Hospital of Hematology of the Chinese Academy of Medical Sciences and CCCG-ALL (Child Oncology Committee of the Chinese Anti-Cancer Association-Acute Lymphocytic Leukemia Collaborative Group) conducted a report on "Vincristine + Dexamethasone in Children's Acute Lymphocytes The latest study on the role and safety of maintenance therapy in leukemia (ALL) patients was published .
